Quarterly ResultMay 11, 2026, 04:19 PM
Elicio Therapeutics Q1 Net Loss $(11.8M); Going Concern Doubt Raised
AI Summary
Elicio Therapeutics reported an increased net loss of $(11.8) million for the first quarter of 2026, compared to $(11.2) million in the prior year. The company's cash and cash equivalents significantly decreased to $14.9 million, and it recorded a total stockholders' deficit of $(1.4) million. These financial conditions, coupled with ongoing operating losses, led management to express substantial doubt about the company's ability to continue as a going concern, despite raising $8.0 million through at-the-market equity programs during the quarter.
Key Highlights
- Net loss for Q1 2026 was $(11.8) million, compared to $(11.2) million for Q1 2025.
- Cash and cash equivalents decreased to $14.9 million as of March 31, 2026, from $18.6 million at December 31, 2025.
- Total stockholders' deficit was $(1.4) million as of March 31, 2026, down from $1.6 million equity at December 31, 2025.
- Accumulated deficit reached $245.5 million as of March 31, 2026.
- Net cash used in operating activities was $(11.6) million for Q1 2026, up from $(10.1) million in Q1 2025.
- Net cash provided by financing activities was $8.0 million for Q1 2026, primarily from ATM offerings.
- Management raised substantial doubt about the company's ability to continue as a going concern.
- Issued and sold 819,157 shares of common stock through ATM programs for $8.0 million net proceeds in Q1 2026.
Price Impact
More from ELTX